Healthcare
Spanish stocks - Factors to watch on Jan 24
- January 24, 2023 08:55 AM CET | Reuters

287 Jan 24 (Reuters) - The following Spanish stocks may be affected by newspaper reports and other factors on Tuesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:
Pharma Mar's Licensing Partner Receives Full Approval For Commercialisation For Zepzelca In Mexico
- January 24, 2023 08:42 AM CET
- Reuters
CORRECTED-(OFFICIAL)-Spanish stocks - Factors to watch on Jan 18
- January 18, 2023 09:51 AM CET
- Reuters
High power prices drive some patients in Spain into poverty
- January 18, 2023 09:03 AM CET
- Reuters
Oryzon Says First Patient Enrolled In Phase II Collaborative Study With Iadademstat
- January 18, 2023 08:30 AM CET
- Reuters

Spanish stocks - Factors to watch on Jan 18
- January 18, 2023 08:15 AM CET | Reuters
Jan 18 (Reuters) - The following Spanish stocks may be affected by newspaper reports and other factors on Wednesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy
Read More...
Oryzon Genomics Informs On Conversion Of Convertible Bonds
- January 17, 2023 08:46 AM CET | Reuters
Jan 17 (Reuters) - Oryzon Genomics SA: * ANNOUNCES CONVERSION OF CONVERTIBLE BONDS * INVESTOR NICE & GREEN HAS REQUESTED A NEW CONVERSION OF BONDS FOR AN AMOUNT JOINT FACE VALUE OF 1.9 MILLION EUROS,
Read More...
Prim Early Terminates Buy-Back Programme After Acquiring 0.45% Of Its Share Capital
- January 11, 2023 04:17 PM CET | Reuters
Jan 11 (Reuters) - Prim SA: * EARLY TERMINATION OF BUY-BACK PROGRAMME * COMPANY HAS REACHED AMOUNT OF EUR 998,942.85 TERMINATING OWN SHARES REPURCHASE PROGRAMME, PRIOR TO EXPIRATION DATE SET FOR JAN
Read More...
Grifols Achieves Positive Topline Results From Phase 3B Study Of Fibrin Sealant
- January 11, 2023 02:07 PM CET | Reuters
Jan 11 (Reuters) - Grifols SA: * ACHIEVES POSITIVE TOPLINE RESULTS FROM PHASE 3B STUDY OF ITS FIBRIN SEALANT TO TREAT SURGICAL BLEEDING IN PEDIATRIC PATIENTS * ALL PRIMARY AND SECONDARY ENDPOINTS MET,
Read More...
Atrys Health Approves Capital Increase Of 6,094 Euros
- December 30, 2022 06:18 PM CET | Reuters
Dec 30 (Reuters) - Atrys Health SA: * APPROVES CAPITAL INCREASE OF COMPANY BY OFFSETTING CREDITS FOR TOTAL NOMINAL AMOUNT OF 6,093.92 EUROS AND A TOTAL SHARE PREMIUM OF 4.3 MILLION EUROS BY ISSUING
Read More...
Pharma Mar Initiates First Human Clinical Trial Of New Molecule For Cancer Patients
- December 30, 2022 08:33 AM CET | Reuters
Dec 30 (Reuters) - Pharma Mar SA: * INITIATES FIRST HUMAN CLINICAL TRIAL OF A NEW MOLECULE, PM534, FOR CANCER PATIENTS * NEW MOLECULE HAS BEEN TESTED IN THE LABORATORY, BOTH IN CELL CULTURES (IN VITRO
Read More...
Spanish stocks - Factors to watch on Dec 28
- December 28, 2022 08:40 AM CET | Reuters
Dec 28 (Reuters) - The following Spanish stocks may be affected by newspaper reports and other factors on Wednesday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy
Read More...
Atrys Buys 100% Of Initia Oncologia And 70% Of Initia Research For Aggregate Amount Of 2.3 Mln Euros
- December 28, 2022 07:46 AM CET | Reuters
Dec 28 (Reuters) - Atrys Health: * SAID ON WEDNESDAY IT ACQUIRED 100% OF INITIA ONCOLOGIA AND 70% OF INITIA RESEARCH (INITIA) * AGGREGATE AMOUNT PAID FOR BOTH COMPANIES AMOUNTS TO 2.3 MILLION EUROS (
Read More...
Atrys Health Signs Contract To Sell 24.9% Of Professional Group Conversia To Arraigo NW Segundo
- December 23, 2022 07:27 AM CET | Reuters
Dec 23 (Reuters) - Atrys Health SA: * SAID ON THURSDAY SIGNED CONTRACT TO SELL 24.9% OF SHARES OF PROFESSIONAL GROUP CONVERSIA TO ARRAIGO NW SEGUNDO * AGREED PRICE AMOUNTS TO 20 MILLION EUROS, OF
Read More...
Pharma Mar Leads Research Project In Search Of Immunotherapies Based On Marine-Derived Compounds
- December 22, 2022 08:54 AM CET | Reuters
Dec 22 (Reuters) - Pharma Mar SA: * LEADS TERINMUN INITIATIVE, RESEARCH CONSORTIUM IN SEARCH OF IMMUNOTHERAPIES BASED ON MARINE-DERIVED COMPOUNDS * PROJECT APPROVED IN CALL FOR PUBLIC-PRIVATE
Read More...